NEWS
CBPartners Publishes Emerging Markets HTA Review Findings in Journal of Pharmaceutical Health Services Research May 31, 2013
CBPartners Invited to Lead Workshop on Orphan Disease Drug Access and Pricing at 2013 ISPOR International Meeting March 14, 2013
CBPartners Leads Full-Day Conference on Biosimilar Development and Commercialisation at the 2013 IBC Biosimilars Conference February 28, 2013
CBPartners Releases New Thought Piece on HTA in the Emerging Markets January 24, 2013
PRACTICES
PRICING & MARKET ACCESS
In this new economic era, how can we balance price with access?
VALUE DEMONSTRATION
With low-cost standard of care and a demand for real-world data, how can we effectively communicate value?
GOVERNMENT POLICY ADVISORY
What are other governments doing to contain cost and drive local innovation - and how can we be a part of it?
PORTFOLIO OPTIMISATION
Considering market and payer realities, how do we adapt and how do we value adaptation?
COMMERCIAL PLANNING
How do we meet our stakeholder needs given the unique nature of our brand?
CBPARTNERS PERSPECTIVES
International Reference Pricing: New Rules for a New Era
April 2012
Cyrus A. Chowdhury
Payer Prophecy: Pricing & Access Optimisation by Trial Design
June 2012
Rachel Beckerman
Spanish HTA
June 2012
Monica Martin de Bustamante
CONTROLLED RELEASE
Click here to request a copy
CBPARTNERS THINKING
SCOTUS on ACA
June 29, 2012
Yesterday, on its last day in session, the US Supreme Court announced its ruling on President Obama's signature legislation, the Patient Protection and Affordable Care Act (ACA). In an unexpected move, conservative Chief Justice Roberts sided with the four generally left-leaning Justices Breyer, Ginsburg, Kagan, and Sotomayor in upholding the law and its central provision, the individual mandate for healthcare coverage. In his opinion, Chief Justice Roberts dismissed the applicability of the Commerce Clause and instead opted for a less expansive interpretation of the US Constitution, declaring... Continue
ROCHE Wins Right To Use Crenezumab in Early Intervention Study in Colombia
May 15, 2012
ROCHE has won the right to use their experimental therapy, Crenezumab, in an early intervention trial in Colombia. The study will look at a patient population suffering from early onset dementia, with some individuals developing symptoms as early as 30 years of age.
Recent efforts by drug companies have fallen earlier in the disease progression spectrum. It remains to be seen how willing payers will be to reimburse... Continue
NICE Reverses Decision on ZYTIGA Based on Updated Patient Access Scheme and New Data
May 16, 2012
It was rather unsurprising that NICE revised their original negative stance on ZYTIGA. Today, England / Wales' HTA body positively recommended ZYTIGA for use in castration-resistant metastatic prostate cancer patients following treatment with docetaxel.
Although additional data was ... Continue
